Comparing Cardiac Contractility Modulation and Cardiac Resynchronization Therapy in Adults with Chagas Heart Disease and Advanced Heart Failure

What this Trial Is About

Researchers are studying patients with Chagas cardiomyopathy CCC, a serious heart condition caused by the parasite Trypanosoma cruzi, which affects millions primarily in Latin America and increasingly worldwide due to migration. This trial compares two implantable devices to improve heart function in patients with advanced heart failure, severe systolic dysfunction, and specific electrical heart patterns, focusing on how cardiac contractility modulation CCM compares to cardiac resynchronization therapy CRT. Participants receive either a CCM device implanted to enhance heart muscle contraction or a CRT device designed to improve heart rhythm coordination. The study evaluates the effects of these devices over a six-month period, tracking quality of life and heart performance. CCM works by stimulating the heart muscle during a specific phase of its activity to boost contraction strength, while CRT targets rhythm synchronization. Both groups are monitored to assess clinical and functional responses. Throughout the study, participants undergo assessments including quality of life questionnaires, heart function tests like global longitudinal strain GLS, six-minute walk tests, and heart failure classification evaluations at the start and after six months. Researchers also record hospitalizations related to heart failure during the study. This comprehensive monitoring aims to understand which device better supports patients heart function and daily living over the trial timeline ending in December 2027.

Cardiac Contractility Modulation in Chagas Heart Disease